Is Catheter Ablation Better Than Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation?

Balaji Natarajan, MD¹ Srishti Nayak, MD² Ramdas G. Pai, MD¹

¹Department of Cardiology, University of California Riverside School of Medicine, Riverside, California

²Department of Cardiovascular Medicine, Loma Linda University School of Medicine, Loma Linda, California

Address for correspondence Ramdas G. Pai, MD, FACC, FRCP, Department of Cardiology, University of California Riverside School of Medicine, Riverside, CA 92507 (e-mail: ramdas.pai@medsch.ucr.edu).

Int J Angiol 2020;29:131–140.

Abstract

Keywords

- ▶ atrial fibrillation
- ▶ ablation
- ▶ radio frequency ablation
- ▶ stroke
- ▶ pulmonary vein
- ▶ left atrium
- ▶ survival

Long-standing atrial fibrillation is associated with significant morbidity including stroke and development of heart failure. Patients also report poor quality of life as a result of debilitating symptoms or treatment side effects from antiarrhythmic medications. Radio frequency or cryothermal mediated catheter ablation has a central role in the management of symptomatic patients with paroxysmal or persistent atrial fibrillation. Circumferential pulmonary vein isolation is vital to the success of this therapy and other ancillary techniques have been described, especially for persistent atrial fibrillation. Several randomized controlled studies have been reported over the last two decades studying important clinical outcomes in patients with atrial fibrillation. In this article, we aim to provide a review of the major studies that have helped define the role of catheter ablation in the management of symptomatic atrial fibrillation in patients with both diseased and structurally normal hearts.

Rhythm control of atrial fibrillation (AF) is usually preferred in symptomatic patients and can be achieved either by using antiarrhythmic drugs (AADs) or by catheter ablation (CA) using either radio frequency or cryothermal energy. Vaughan Williams Class IC and Class III AAD are most commonly used, and they have significant side-effect profile including risk of ventricular arrhythmias, major contraindications, drug–drug interactions, and systemic toxicity, apart from poor overall efficacy. Over the past decade, circumferential pulmonary vein isolation has evolved from being a “novel” concept into a routine strategy to help manage patients with symptomatic AF. The primary aim of CA is to electrically isolate ectopic premature impulses that serve to trigger AF and eliminate them at the site of their origin around the pulmonary veins. Additional techniques to modify the left atrial substrate such as linear ablations of the left atrial posterior wall, focal complex fractionated atrial electrogram-guided ablations, ablation of ganglionic plexi, and areas of scar and other nonpulmonary vein triggers (superior vena cava or interatrial septum) have shown additive benefit, albeit at the risk of

greater procedure-related complications. The purpose of this article is to provide a concise review of the compelling literature that has helped shape current guidelines for the use of CA in the management of AF, and its role in special populations.

The first-time success rate of CA in atrial flutter is excellent and ranges in the 90 to 95%. In contrast, this is ~50 to 70% in AF and improves to 80 to 90% with repeat procedures. Success of therapy is significantly much better in patients with paroxysmal AF compared with those with persistent AF. This largely explains the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) recommendations for management of AF. CA has a Class I indication in symptomatic AF patients who are refractory or intolerant to at least 1 Class I/III AAD if paroxysmal, Class IIa if persistent and Class IIb if of the long-standing persistent (> 12 months) type. Additionally, CA may also be attempted as the first rhythm control strategy prior to trial of AAD in case of recurrent symptomatic paroxysmal (Class IIa) or persistent AF (Class IIb), although

Fig. 1 Timeline of major randomized controlled trials characterizing the role of catheter ablation in symptomatic patients with atrial fibrillation.

we do not have strong evidence for this recommendation.¹ The 2016 ESC² and 2017 HRS/EHRA/ECAS/APHRS/SOLAECE³ expert consensus statement on catheter and surgical ablation of AF also endorse the above recommendations. We will discuss the major randomized controlled trials (RCTs) that shaped the above guidelines in the following sections (►Fig. 1). Apart from chronicity and pattern of AF, patient characteristics such as advanced age, presence of structural heart disease such as heart failure (HF) and dilated left atrium (LA), presence of other comorbidities such as sleep apnea and obesity, and more importantly, operator volumes and experience also dictate success with these procedures. The role of CA in various patient populations is summarized (►Table 1).

Role of Catheter Ablation in Structurally Normal Hearts

Several small RCTs of symptomatic patients who have previously failed or intolerant to AAD have shown that CA is associated with less incidence of early and late AF recurrence,⁴⁻⁷ reduction in AF duration^{6,7} and frequency of episodes,⁴ decreased need for hospitalizations,^{6,8} and have shown overall improvement in quality of life (QOL) and functional capacity measured through various standardized metrics.^{4,7} Data reported from a large Canadian Registry showed that more than 50% patients with paroxysmal AF will eventually progress to persistent AF or die from an event within 10 years.⁹ Also, due to progressive left atrial remodel-

ing and fibrosis, success of maintaining sinus rhythm declines with longer duration of disease (AF begets AF). This raises an important question; should we ablate patients early in the course of their disease? The RAAFT-1 study¹⁰ sought to evaluate a strategy of initial CA compared with AAD therapy in a group of 70 treatment naïve patients with symptomatic AF. Although small, this study reported lower AF burden, reduced cardiovascular hospitalization, and improved QOL in AF patients treated with an initial strategy of CA at 1-year follow-up. A much larger MANTRA-PAF study¹¹ ($n = 294$) found that early CA was associated with greater freedom from AF recurrence and symptomatic recurrence at 2 years, and this effect was sustained even at 5-year follow-up in patients with paroxysmal AF. The RAAFT-2 study¹² also reported similar findings at 2-year follow-up but observed much higher complication rates with early CA (overall rate of 9% with a 6% incidence of cardiac tamponade) when compared with contemporary studies. However, these studies were hampered by slow recruitment due to highly selected study populations, routine protocol deviations by the subjects, differences in measured primary outcomes, and wide differences in CA techniques and operator experience. More importantly, most RCTs were underpowered to report hard outcomes such as mortality and stroke rates. This has led to confusion among referring providers and overall a lower acceptance of CA as an initial strategy in symptomatic AF patients among electrophysicians.

In contrast, the data are far more compelling in favor of CA for patients who have failed or unable to tolerate prior

Table 1 Trials addressing ablation for atrial fibrillation

Study	n	Study population	Comparator arm	Ablation technique	Cross-over rate	Monitoring strategy	Follow-up	Primary findings	Secondary findings	Complication rate
RAAFT-1 trial ^a	70	Paroxysmal AF and persistent AF (~4%); mean age 53 y	CA (n = 33) versus AAD (n = 37)	PVI	None	Holter monitoring, symptom journal	12 mo	At 1-y follow-up: 63% of AAD group had at least 1 recurrence of symptomatic AF compared with 13% in CA arm ($p < 0.001$). Hospitalization occurred in 54% patients in AAD arm versus 9% in CA arm ($p < 0.001$). In the AAD group, the mean (SD) number of AF episodes decreased from 12 (7) to 6 (4), after initiating therapy ($p = 0.01$).	At 6-mo follow-up: the improvement in QOL was significantly better in the CA group in 5 subclasses of the Short-Form 36 health survey	CA = 3% (moderate PV stenosis) AAD = 8.6%
Wazni et al ¹⁰										
JAMA 2005										
APAF study	198	Paroxysmal AF; mean age 56 y	CA (n = 99) versus AAD (n = 99)	PVI	AAD to CA: 42 (45%) CA to AAD: 0	ECG, Holter monitoring, event monitor, symptom journal	12 mo	93% of patients randomized to ablation were free of recurrence at the end of follow-up as compared with the 35% of patients in AAD arm ($p < 0.001$) at 1-y follow-up	CA was associated with fewer CV hospitalizations ($p < 0.01$), improved LVEF ($p = 0.003$) and reduced AF duration ($p = 0.015$)	CA = 1% (1 pericardial effusion not requiring intervention) AAD = 23%
Pappone et al ⁶										
JACC 2006										
A4 study	112	Paroxysmal AF; mean age 51 y	CA up to 3 attempts (n = 53) versus AAD (n = 59)	PVI	AAD to CA: 37 (63%) CA to AAD: 5 (9%)	ECG, SF-36, AF symptom frequency and severity checklist, Holter monitoring, echo and treadmill stress test	12 mo	23% in AAD group versus 89% in CA group had no recurrence of AF in 1 y ($p = 0.0001$)	CA arm had significantly lower AF burden ($p < 0.0001$), higher mental and physical component scores ($p = 0.01$) and lower symptom severity ($p < 0.001$). There was no difference noted in LA size, LVEDD, and LVEF between the two groups	CA = 2% (1 tamponade, 1 PV stenosis) AAD = 6%
Jais P et al ⁸										
Circulation 2008										
PABA CHF study	81	Paroxysmal (49%) or persistent AF (51%) with LVEF < 40%; mean age 60 y	PVI (n = 41) versus AV nodal ablation with BIV pacing (n = 40)	PVI and AV nodal ablation with BIV pacing	None	Composite of MLWHF score, LVEF on echo and 6MWD	6 mo	PVI group scored better on MLWHF (60 ± 8 vs. 82 ± 14 , $p < 0.001$), achieved greater	In CA group, patients on AAD were 88% free of AF at 6 mo as compared with 71%	CA = 17% (1 pericardial effusion, 2 PV stenosis) AV Ablation = 7%
Khan et al ¹⁷										

(Continued)

Table 1 (Continued)

Study	n	Study population	Comparator arm	Ablation technique	Cross-over rate	Monitoring strategy	Follow-up	Primary findings	Secondary findings	Complication rate
NEJM 2008								6MWD (340 vs. 297 m, $p < 0.001$), and a higher LVEF (35 vs. 28%, $p < 0.001$).	patients after AV nodal ablation and BIV pacing	
THERMOCOOL AF study	167	Paroxysmal AF; mean age 55 y	CA (n = 101) versus AAD (n = 61)	PVI and ancillary ablations	AAD to CA: 36 (35%) after failing primary end point	ECG at follow-up visits, transtelephonic and Holter monitoring	9 mo	CA patients remained free from protocol-defined treatment failure (66 vs. 16%); free of symptomatic recurrent atrial arrhythmia (70 vs. 19%) and free of any recurrent atrial arrhythmia (63 vs. 17%) compared with AAD arm	CA patients reported greater improvement in SF-36 mental and physical scores and significantly lower symptom frequency and severity	CA = 4.9% (1 pericardial effusion) AAD = 8%
Wilber et al ⁴										
JAMA 2010										
ARCH-HF trial	50	Persistent AF in chronic HF patients with LV EF < 35%; mean age 63 y	CA (n = 25) versus rate control RC (n = 26)	PVI and ancillary ablations	RC to CA: 1 (4%) CA to RA: 0	ECG at follow-up visits, 48-h ambulatory monitoring at 6 and 12 mo, device interrogations and echo	12 mo	Peak oxygen consumption significantly increased in the CA compared with RC (difference +3.07 mL/kg/min) at 12 mo	CA improved MLWHF score ($p = 0.019$) and B-type natriuretic peptide ($p = 0.045$) and showed non-significant trends toward improved 6 MWD ($p = 0.095$) and LVEF ($p = 0.055$)	One patient with tamponade in CA arm.
Jones et al ¹⁶										
JACC 2013										
MANTRA—PAF study ^a	294	Paroxysmal AF; mean age 55 y	AAD (n = 148) versus CA (n = 146)	PVI	AAD to CA: 54 (36%) CA to AAD: 13 (9%)	QOL survey, 7-d Holter monitor; Patient logbook; echo	24 mo	No episodes of AF reported in 85% of RFA group compared with 71% in AAD group ($p = 0.004$). At 24-mo follow-up visit, burden of atrial fibrillation was reduced with CA compared with AAD: 9 versus 18% ($p = 0.007$). Above results were durable at 5-y follow-up also	Freedom from any atrial fibrillation: 85% versus 71% at 5-y follow-up ($p = 0.004$) Decreased ASTA index in CA group at 24 mo 47 versus 57% ($p < 0.001$)	CA = 17% (3 tamponades, 1 PV stenosis) AAD = 14%
Cosedis Nielsen J et al ¹¹										
NEJM 2012										
STOP AF trial	245	78% paroxysmal, 22% early persistent; mean age 57 y	Cryoablation (n = 163) versus AAD (n = 82)	PVI and ancillary ablations	AAD to CA: 65 (79%) at 12-mo follow-up	ECG at follow-up visits, transtelephonic and Holter monitoring	12 mo	Cryoablation therapy successfully isolated ≥ 3 PV in 98.2% and all 4 PV in 97.6%. This was achieved with balloon catheter alone	None	All serious adverse events: cryoablation 12.3% versus AAD 14.6%; $p = 0.69$; 5 PV stenosis, 26 phrenic
Packer et al ⁵										
JACC 2013										

Table 1 (Continued)

Study	n	Study population	Comparator arm	Ablation technique	Cross-over rate	Monitoring strategy	Follow-up	Primary findings	Secondary findings	Complication rate
CAMTAF study	50	Persistent AF, and LVEF <50%; mean age 57 y	CA (n = 26) versus AAD (n = 24)	PVI and ancillary ablations	None	ECG, serum BNP, echo, treadmill stress test, peak exercise VO ₂ max	6 mo; 12 mo for CA arm	Freedom from AF after the last CA was achieved in 81% at 6 mo and was sustained up to a year in 73% patients off AAD. At 6 mo, CA group had greater LVEF which was sustained on 1-year follow-up. The CA arm also had greater reduction in LV end-systolic volume at 6 mo (-14 vs. -4%).	At 6 mo, CA resulted in improved exercise capacity and HF symptoms, BNP (126 vs. 327 pg/mL), NYHA class (1.6 vs. 2.4) and QOL (MLWHF score 23.7 vs. 47) compared with AAD	nerve palsy, 1 tamponade)
Hunter et al ¹⁸										CA = 7% (1 stroke, 1 tamponade)
Circulation 2014										AAD = 8%
RAAFT-2 trial ^a	127	Paroxysmal AF; mean age 55 y	CA (n = 66) versus AAD (n = 61)	PVI and ancillary ablations	AAD to CA: 26 (42%) CA to AAD: 6 (9%)	ECG or transtelephonic monitor	24 mo	Time to first recurrence of symptomatic or asymptomatic AF, atrial flutter, or atrial tachycardia lasting more than 30 s occurred in 44 patients (72.1%) in the AAD group and 36 pts (54.5%) in the CA (p = 0.02).	59% in the AAD group and 47% in the CA group experienced the first recurrence of symptomatic AF, atrial flutter, atrial tachycardia (p = 0.03). Total number of recurrent AF, flutter or atrial tachycardia episodes was significantly lower (213 vs 502) in CA arm. QOL measurements based on surveys were not significantly different between CA and AAD	CA = 9% (6% tamponade) AAD = 3%
Morillo et al ¹²										
JAMA 2014										
AATAC study	203	Persistent AF; presence of dual chamber ICD or	CA (n = 102) versus amiodarone (n = 101)	PVI and ancillary ablations	Drug to CA: 25 (25%)	ECG, echocardiogram, MLHFQ, and 6MWT	24 mo	71 (70%) patients in gr CA group were recurrence free after an	Over the 2-y follow-up, unplanned hospitalization rate was 31% in CA and	CA = ~1% (pericardial effusion)
DiBiase et al ⁸										

(Continued)

Table 1 (Continued)

Study	n	Study population	Comparator arm	Ablation technique	Cross-over rate	Monitoring strategy	Follow-up	Primary findings	Secondary findings	Complication rate
Circulation 2016		LVEF < 40%. Mean age 61 y			CA to drug: 15 (15%)			average of 1.4 ± 0.6 procedures in comparison with 34 (34%) in amiodarone group ($p < 0.001$).	57% in drug arm; $p < 0.001$, showing a 45% relative risk reduction. A significantly lower mortality rate was observed in CA (8 vs. 18%; $p = 0.037$).	Amiodarone = 18% ($p = 0.037$).
CAMERA-MRI study	66	Persistent AF; LVEF < 45%; no CAD. Mean age 60 y	CA ($n = 33$) versus AAD ($n = 33$)	PVI and posterior wall isolation	AAD to CA: 3 (9%) CA to AAD: 0	ECHO, Holter monitor, implantable loop recorder, CMRI, 6MWT, serum BNP	6 mo	LVEF increased 18.3% in CA arm versus 4.4% in drug group. ($p < 0.0001$). Freedom from AT/AF (>30 s in RFA group) was 56% and on AAD was 75%.	LVEF was significantly decreased in the CA group (24 vs 20 mL/m ² ; $p = 0.007$). Left atrial volume was also significantly decreased in the CA group with no change in the drug group ($p < 0.0001$)	CA = 6% AAD = 12%
CASTLE-AF study	397	Paroxysmal and persistent AF with LVEF < 35% or implanted ICD; median age 64 y	CA ($n = 179$) versus AAD ($n = 184$)	PVI	AAD to CA: 18 (9%) CA to AAD: 28 (15%)	ICDs or CRT-Ds interrogation, ECHO, 6MWT	60 mo	Death or hospitalization for worsening HF occurred in significantly fewer patients in the CA group (28.5 vs. 44.6%; $p = 0.006$) compared with AAD	Heart failure-related admissions was significantly lower in CA group (20.7 vs. 35.9%; $p = 0.004$). CV deaths were also lower in CA arm (11 vs. 22%; $p = 0.009$)	CA = 13.4% (3 pericardial effusion, 1 pulmonary vein stenosis) AAD = 25.0%
CABANA study	2200	Paroxysmal (43%), persistent and long-standing persistent (47%); mean age 55 y	CA ($n = 1108$) versus AAD ($n = 1096$)	PVI and ancillary ablations.	AAD to CA: 301 (28%) CA to AAD: 99 (9%)	Event monitoring every 6 mo	48 mo	Composite of death, disabling stroke, serious bleeding, or cardiac arrest at 4 y for CA versus AAD (8 vs. 9.2%) was not significantly different	All-cause mortality (5.2 vs. 6.1%), $P = NS$ Death or CV hospitalization (51.7 vs. 58.1%), $p = 0.001$ AF recurrence (49.9 vs. 69.5%), $p < 0.001$	CA = 5% (8 tamponade, 1 pulmonary vein stenosis, 1 phrenic nerve injury)
Packer et al.										
JAMA 2019										

Abbreviations: AAD, antiarrhythmic drugs; AF, atrial fibrillation; ASTA, arrhythmia-specific questionnaire in tachycardia and arrhythmia; AV, atrioventricular; BIV, biventricular; BNP, brain natriuretic peptide; CA, catheter ablation; CAD, coronary artery disease; CMRI, cardiac magnetic resonance imaging; CV, cardiovascular; ECG, electrocardiography; EDD, end-diastolic dimension; HF, heart failure; ICD, inverter cardiac defibrillator; LA, left atrium; LVEF, left ventricular ejection fraction; LV ESV, left ventricular end-systolic volume; MLWHF, Minnesota Living with Heart Failure questionnaire; NS, nonsignificant; NYHA, New York Heart Association; PVI, pulmonary vein isolation; QOL, quality of life; SF-36, 36-Item Short-Form Health Survey; 6MWT, 6-minute walk distance test.

^aStudies that evaluated catheter ablation as first line therapy prior to antiarrhythmic drug therapy.

antiarrhythmic therapy. The much-anticipated CABANA trial was reported last year, and for the first time, a study provided long-term data on hard end points (death, stroke, and cardiac arrest) for ablation versus drug therapy in a large group of patients ($n = 2,204$) with paroxysmal or persistent AF who had previously failed AAD therapy. The primary outcome (composite of death, disabling stroke, serious bleeding, or cardiac arrest) was not significantly different between the groups (8% in CA vs. 9% in AAD group; $p = 0.30$). None of the isolated primary end points achieved statistical significance either; however, the investigators noted a significant reduction in AF burden and recurrence, as well as reduction in hospitalizations and improvement in QOL in patients after CA at 5 years. Also, this study documented a significantly lower incidence of major complications ($\sim 5\%$)¹³ such as cardiac tamponade, pulmonary vein stenosis, and phrenic nerve injury in the CA ablation group as compared with previous RCTs. This supports the notion that CA, if done in high volume centers by experienced providers, can be a relatively safe procedure and helps to improve symptoms and QOL. Considering that there were large protocol deviations among the study participants (study crossover rate: ablation to drug—9.2%; drug to ablation—27.5%), the CABANA trial authors had also reported on “as-treated” analysis, where the groups were analyzed based on the treatment received instead of their originally assigned group. In contrast to the intention-to-treat analysis, the results overwhelmingly favored ablation for the composite as well as individual components of the primary end point. This became a point of controversy among experts in the field and the jury was divided regarding the mortality benefit of CA. Noseworthy et al¹⁴ reported their findings from a retrospective cohort analysis of a large national database by replicating the CABANA study protocol and included patients who underwent CA within the CABANA trial recruitment period (2009–2016). In this large group of patients ($n = 183,760$), the primary outcome (composite of death, disabling stroke, serious bleeding or cardiac arrest) strongly favored CA compared with AAD (hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.70–0.81; $p < 0.001$). Individual primary end points were also significantly lower in CA arm except for major bleeding. This data, although supports the findings from the “as-treated” analysis of the CABANA trial, needs to be interpreted with caution due to their observational nature and the chance for residual confounding. Nevertheless, this study supports the argument that CA might have a mortality benefit in the “real world” and the findings of the “as-treated” analysis from CABANA cannot be entirely discounted as a chance occurrence.

Role of Catheter Ablation in Patients with Heart Failure

AF and HF co-exist in many patients and episodes of rapid AF in patients with pre-existing HF can worsen cardiac output due to loss of “atrial kick” and further impaired diastolic filling. Conversely, long-standing HF can cause increases in filling pressures and LA stretch from volume overload,

disrupt ionic currents that regulate intracellular calcium, and cause imbalances in autonomic function that can facilitate the genesis of AF. Moreover, HF has also been shown to cause interstitial fibrosis and remodeling of the LA, and this can serve as a substrate to propagate AF thereby setting up a vicious cycle of worsening HF.¹⁵ AADs have a limited role to play in HF due to potential toxicities, and this led to interest in the potential role of CA to restore sinus rhythm in these patients. Early studies have shown us that CA can cause improvement in the left ventricular ejection fraction (LVEF) (~ 5 – 10%) from baseline, decrease brain natriuretic peptide levels and HF hospitalizations and improve both QOL and functional capacity in the form of increase in peak oxygen consumption and 6-minute walk distances, an important prognostic indicator.^{16–19} However, most studies were underpowered to study mortality. A good example is the AATAC study⁸ that found a 56% relative risk reduction for mortality with CA when compared with amiodarone therapy at 2-year follow-up, but it was underpowered to study this end point ($n = 203$). Additionally, the PABA CHF¹⁷ study showed superiority of CA over atrioventricular (AV) nodal ablation with biventricular pacing in terms of freedom from AF at 6 months, and improvements in QOL, functional capacity, and LVEF from baseline in patients with LVEF $< 40\%$.

The CASTLE-AF trial¹⁹ was the first adequately powered RCT to report a mortality benefit with CA in HF patients. This study enrolled 397 patients with symptomatic paroxysmal or persistent AF and HF with a LVEF of $\leq 35\%$. The composite primary end point of all-cause mortality and unplanned HF hospitalization was significantly lower in CA arm versus medical therapy—rate or rhythm control (28.5 vs. 44.6%; $p = 0.007$) at a median follow-up of 37.8 months. Additionally, the CA ablation group also showed a median LVEF improvement of 8% (2.2–19.1%) and greater freedom from AF (63.1 vs. 21.7%; $p < 0.001$) at 5-year follow-up visit. Another RCT presented around the same time; the CAM-ERA-MRI study²⁰ challenged the notion that rate control is equivalent to rhythm control in persistent AF patients with LV dysfunction. This study confirmed improvement in LVEF and favorable chamber remodeling with CA, but additionally also observed that ablated patients with myocardial scar (presence of delayed gadolinium enhancement on cardiac magnetic resonance imaging) had greater improvements in absolute LVEF by 10.7% and normalization of LV function at 6 months (73 vs. 29%; $p = 0.0093$). Interestingly, although the CABANA trial was a negative study overall, a recent abstract presented by the authors at the HRS meeting described the outcomes in 886 HF patients (40% of the study population). CA showed a significant reduction in the primary end point (HR: 0.66; 95% CI: 0.43–0.99) and in all-cause mortality (HR: 0.59; 95% CI: 0.36–0.96). Additionally, AF recurrence was also much improved after CA (HR: 0.58; 95% CI: 0.44, 0.75).²¹ The compelling data from above-discussed RCTs have secured a Class IIa recommendation in the 2016 ESC guidelines² and a Class IIb recommendation in the 2019 focused update of the AHA/ACC/HRS guideline for the management of patients with AF and HF with reduced EF (HFrEF).²² Although the prevalence of AF is the same irrespective of whether EF is

reduced or preserved, we do not have sufficient data on the efficacy of CA in HF with preserved EF (HFpEF) population at this time. However, a recent analysis of retrospective registry data from the Mayo AF Symptom Inventory²³ showed that there were no significant differences in AF burden or functional improvement between HFrEF and HFpEF patients, suggesting that this heterogeneous group of patients might also benefit from CA.

Role of Catheter Ablation in Special Populations

Certain high-risk populations are under-represented in trials, and hence adequate evidence is not available to guide recommendations for CA in these special groups.

1. *AF in patients at extremes of age*: The elderly (> 80 years of age) patients have a high prevalence of AF and usually have multiple associated comorbidities that drive the severity of their symptoms. Especially, they have a high risk of stroke and data strongly support anticoagulation in this population as reflected in the CHA2DS2-VASc scoring system (where age > 75 years is considered a major risk factor). Multiple studies have reported similar outcomes with CA in the elderly when compared with the younger population, and the guidelines do not support a less aggressive strategy based on age. However, these patients found suitable for CA should be carefully selected keeping in mind that there is higher risk of post-procedure complications and higher need for AAD postablation. In contrast, young patients (age < 45 years) have lower rates of AF recurrence and lower procedural complication rates, possibly due to lesser comorbid conditions when compared with the older AF population undergoing CA. Based on unpublished subgroup analysis from the CABANA trial with patients stratified as <65, 65 to 74 and > 75 years of age, it was reported that recurrent AF was reduced equally in all three groups, but the younger population (<65 years) showed significant reduction in all-cause mortality (HR: 0.41; 95% CI: 0.19–0.90). CA could be a potential first-line rhythm control option for young patients, but this is not supported by strong evidence at this time.
2. *AF in hypertrophic cardiomyopathy (HCM)*: Development of AF in HCM patients is more common in the general population and is associated with high mortality. Moreover, AF episodes are poorly tolerated and there is a high stroke risk in HCM patients. A rate control strategy is usually preferred first, with the addition of AAD such as amiodarone or disopyramide for rhythm control. Small studies have shown that CA in HCM patients is effective to suppress AF recurrences, especially in patients with paroxysmal AF and small atria, but need for repeat procedures is high. CA currently has a Class IIa recommendation from all professional society guidelines in HCM patients who fail or do not tolerate initial AAD therapy.
3. *AF in the presence of an accessory pathway*: Incidence of AF is ~15% over 10 years in patients with Wolff–Parkinson–White syndrome and there is high risk of degenerating

into life-threatening ventricular arrhythmias, especially if the accessory pathway has a short anterograde refractory period (< 250 ms). Role of CA in such patients is well-established and carries a Class I recommendation from the ACC. Additionally, the ESC guidelines state that urgent CA is recommended both for primary and secondary prevention in patients in case of cardiac arrest as a Class 1 indication and may be considered in asymptomatic patients with overt pre-excitation after careful counseling (Class IIa).

4. *AF in athletes*: There exists a U-shaped relationship of AF occurrence with exercise, and people at both ends of the spectrum are at high risk of both paroxysmal and persistent AF. They tend to be mostly vagal mediated, with atrial dilatation and chronic inflammation potentially playing a role. Studies are divided on the benefit of CA in athletes with some suggesting definite benefit, while others have found CA to be comparable to drug therapy, although this might be challenging due to profound bradycardia in this population. CA currently carries a Class IIa recommendation as first-line therapy in athletes based on professional society guidelines.
5. *AF in adults with congenital heart disease*: Development of early and late tachyarrhythmias is fairly common in unrepaired atrial septal defects, patients with Fontan circulation and patients with repaired tetralogy of Fallot. Pathogenesis is complex but can be related to hypertrophy and fibrosis of the atria, volume overload state or from scar-related formation of macro-reentry circuits. In such patients, long-term use of AAD can be challenging due to side-effect profile. CA has been shown to be effective in small cohorts of such patients with symptomatic AF, but strong evidence is lacking. At the present time, CA has a Class IIb indication in symptomatic patients with congenital heart disease when performed in experienced centers.

Conclusion

CA is a relatively safe procedure and has proven benefit in alleviating symptoms and improving QOL in patients with symptomatic paroxysmal and persistent AF. CA might have mortality benefit in certain select populations such as younger patients and those with systolic HF. Success of procedure depends upon AF chronicity and comorbid conditions, and outcomes are generally better in experienced centers with high volumes and operator experience. Future studies targeting pathways for neurohormonal and autonomic modulation in addition to pulmonary vein isolation could help explore new avenues in the management of patients with symptomatic AF.

List of Acronyms

RAAFT	Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
CABANA	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation

AATAC	Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD study
PABA CHF	Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart Failure study
CASTLE-AF	Catheter Ablation for Atrial Fibrillation with Heart Failure

Conflict of Interest
None declared.

References

- January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014; 64(21):e1–e76
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;18(11):1609–1678
- Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *J Arrhythm* 2017;33(05):369–409
- Wilber DJ, Pappone C, Neuzil P, et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA* 2010;303(04):333–340
- Packer DL, Kowal RC, Wheelan KR, et al; STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. *J Am Coll Cardiol* 2013;61(16):1713–1723
- Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. *J Am Coll Cardiol* 2006;48(11):2340–2347
- Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. *Circulation* 2008;118(24):2498–2505
- Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation* 2016;133(17):1637–1644
- Padfield GJ, Steinberg C, Swampillai J, et al. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. *Heart Rhythm* 2017;14(06):801–807
- Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA* 2005;293(21):2634–2640
- Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. *N Engl J Med* 2012;367(17):1587–1595
- Morillo CA, Verma A, Connolly SJ, et al; RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *JAMA* 2014;311(07):692–700
- Packer DL, Mark DB, Robb RA, et al; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA* 2019; 321(13):1261–1274
- Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. *Eur Heart J* 2019;40(16):1257–1264
- Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. *JACC Heart Fail* 2019;7(06): 447–456
- Jones DG, Halder SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. *J Am Coll Cardiol* 2013;61(18):1894–1903
- Khan MN, Jaïs P, Cummings J, et al; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *N Engl J Med* 2008;359(17):1778–1785
- Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circ Arrhythm Electrophysiol* 2014;7(01):31–38
- Marrouche NF, Brachmann J, Andresen D, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018;378(05):417–427
- Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. *J Am Coll Cardiol* 2017;70(16):1949–1961
- Douglas L, Packer, Hussein R, Al-Khalidi, Adam P, Silverstein, Jeanne E, Poole, Tristram D, Bahnson, Daniel B, Mark, Kerry L, Lee. Dealing with the double whammy: AF in HF. *Heart Rhythm Society Annual Scientific Sessions*; 2019; San Francisco, CA
- January CT, Wann LS, Calkins H, et al; Writing Group Members. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2019;16(08):e66–e93
- Black-Maier E, Ren X, Steinberg BA, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. *Heart Rhythm* 2018;15(05):651–657